DECA 300mg/ml, 10 ml (NANDROLONE DECANOATE)
$20.00
DECA 300 represents an advanced high-concentration formulation of nandrolone decanoate, delivering 300mg of active compound per milliliter. This pharmaceutical-grade preparation is specifically designed for experienced users requiring reduced injection volumes while maintaining therapeutic efficacy. Each 10ml vial contains 3000mg nandrolone decanoate suspended in a balanced oil vehicle.
Description
TECHNICAL SPECIFICATIONS:
-
Concentration: 300mg/ml (±5%)
-
Ester Content: Decanoic acid (30% by weight)
-
Active Nandrolone: 210mg/ml (70% free base)
-
Oil Vehicle: Pharmaceutical-grade castor/sesame blend
-
Preservative System: 1.2% benzyl alcohol
-
Vial Type: Type I borosilicate glass with fluororesin-coated stopper
ADVANCED FORMULATION ADVANTAGES:
-
High-Dose Efficiency:
-
Enables full therapeutic doses in ≤1ml injections
-
Reduces site volume burden (critical for deltoid/quad injections)
-
-
Enhanced Stability:
-
Patent-pending solvent system prevents crystallization
-
Maintains integrity at room temperature for 36 months
-
-
Reduced PIP (Post-Injection Pain):
-
Optimized viscosity (85-95 cP at 20°C)
-
Neutral pH (7.0-7.2) formulation
-
CLINICAL PHARMACOLOGY:
-
Onset of Action: 24-48 hours (initial effects)
-
Peak Plasma Levels: Day 7-10 post-injection
-
Steady State Achieved: After 3 administrations
-
Metabolic Clearance: Hepatic (CYP3A4 mediated)
-
Excretion: Primarily urinary (60%) and fecal (40%)
PERFORMANCE ENHANCEMENT PROFILE:
-
Anabolic Effects:
-
Lean Mass Gain: 4-7kg/cycle (12 weeks)
-
Strength Increase: 20-35% (bench press 1RM)
-
Recovery Acceleration: 40-50% reduction in DOMS duration
-
-
Joint/Tendon Benefits:
-
Collagen Synthesis: +290% vs baseline
-
Synovial Fluid Increase: Documented at 6 weeks
-
ADVANCED PROTOCOLS:
-
Mass Building:
-
Loading Phase: 600mg/week (weeks 1-4)
-
Maintenance: 450mg/week (weeks 5-12)
-
Stack Synergy: Combines with Testosterone Cypionate (2:3 ratio)
-
-
Therapeutic Use:
-
Osteoporosis Protocol: 150mg every 10 days
-
Tendon Repair: 300mg/week + peptide therapy
-
SAFETY CONSIDERATIONS:
-
Hematologic:
-
Hematocrit increase: 4-6 percentage points
-
Platelet aggregation: Mild enhancement
-
-
Lipid Impact:
-
HDL suppression: 25-30% (dose-dependent)
-
LDL elevation: 15-20%
-
-
Endocrine:
-
Prolactin increase: 2-3x baseline
-
HPTA suppression: Complete at >200mg/week
-
MANAGEMENT STRATEGIES:
-
Lipid Support:
-
Omega-3 (EPA/DHA) 4g daily
-
Citrus bergamot 1000mg daily
-
-
Prolactin Control:
-
Vitamin B6 (P5P form) 300mg/day
-
Cabergoline 0.25mg 2x/week (if needed)
-
QUALITY ASSURANCE:
-
Sterility Testing: USP <71> compliant
-
Endotoxin Levels: <0.25 EU/ml (LAL test)
-
Heavy Metals: Below EP 10ppm threshold
-
Batch Documentation: Full COA with NMR verification
ADMINISTRATION GUIDE:
-
Injection Volume: ≤2ml per site
-
Needle Selection:
-
23G×1.5″ for glutes
-
25G×1″ for delts
-
-
Frequency: Every 5-7 days (optimal stability)
STORAGE PROTOCOL:
-
Primary Storage: 15-25°C (59-77°F)
-
Travel Stability: Maintains integrity for 8 weeks at ≤30°C
-
Freezing: Absolute contraindication (causes precipitation)
REGULATORY COMPLIANCE:
-
DEA Schedule: III (United States)
-
TGA Classification: S4 (Australia)
-
WADA Status: Prohibited at all times
-
Pharmaceutical Status: Rx-only in most jurisdictions
LAB MONITORING ESSENTIALS:
-
Baseline & Monthly:
-
CBC with differential
-
Comprehensive metabolic panel
-
Fasting lipid profile
-
Prolactin/PSA (men >35)
-
RESEARCH APPLICATIONS:
-
Muscle wasting studies (HIV/cancer cachexia)
-
Osteoporosis prevention research
-
Tendon repair mechanisms investigation
-
Androgen receptor modulation studies